Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
Highlights
– In the multicenter nonrandomized PUMP‑2 phase II trial (Franssen et al., J Clin Oncol 2025), HAIP floxuridine combined with systemic gemcitabine–cisplatin produced a 1‑year overall survival (OS) of 80.0% (95% CI, 69.6%–91.9%) among patients with unresectable intrahepatic cholangiocarcinoma (iCCA) confined to the liver, significantly higher than a historical 47% control (P < .001).
– Median OS was 22.3 months (95% CI, 19.7–35.9 months); 3‑year OS was 31.5% (95% CI, 20.4%–48.6%). Objective partial response rate was 44% and disease control at 6 months was 84%.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.